drugset / Trial / NCT07073950

A Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation

NCT07073950

Phase 4 Recruiting 56 enrolled AstraZeneca Parexel · collab
RandomizedCrossoverDouble-blindTreatment

Summary

The purpose of the study is to evaluate the effect of BGF MDI compared with placebo MDI on cardiac and lung function when administered in participants diagnosed with COPD and hyperinflation.

Timeline

Start
2025-11-24
Primary completion
2027-05-31
Completion
2027-05-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Budesonide Small molecule Oral
Subject Formoterol Other / unclassified Oral
Subject Glycopyrronium Unknown Oral